Long-chain n-3 polyunsaturated fatty acids (LC n-3 PUFA) exert beneficial effects on health and they could help to prevent development of obesity and associated metabolic disorders. In our previous studies in mice fed high-fat (cHF; ~60 % calories as fat) diet and maintained at 20 °C, dietary LC n-3 PUFA could counteract accretion of body fat, without inducing mitochondrial uncoupling protein 1 (UCP1) in adipose tissue, suggesting that the anti-obesity effect was not linked to adaptive (UCP1- mediated) thermogenesis. To exclude a possible dependence of the anti-obesity effect on any mechanism inducible by cold, experiments were repeated in mice maintained at thermoneutrality (30 °C). Male C57BL/6J mice were fed either cHF diet, or cHF diet supplemented with LC n-3 PUFA, or standard diet for 7 months. Similarly as at 20 °C, the LC n-3 PUFA supplementation reduced accumulation of body fat, preserved lipid and glucose homeostasis, and induced fatty acid re-esterification in epididymal white adipose tissue. Food consumption was not affected by LC n-3 PUFA intake. Our results demonstrated anti-obesity metabolic effect of LC n-3 PUFA, independent of cold-induced thermogenesis and they suggested that induction of fatty acid re-esterification creating a substrate cycle in white fat, which results in energy expenditure, could contribute to the anti-obesity effect., P. Janovská, ... [et al.]., and Obsahuje seznam literatury
Michal Bauer, Jana Cahlíková, Dagmara Celik Katreniak, Julie Chytilová, Lubomír Cingl, and Tomáš Želinský., Obsahuje bibliografii a bibliografické odkazy, and České a anglické resumé
The contribution deals with the possibilities of legal protection from an undesirable phenomenon
called spam or, more precisely, spamming, pursuant to the Czech and European laws. In particular, the legal forms of protection of personal data, privacy, and personal rights are described in detail along with unfair competition and the law of obligations in tort. Attention is also paid to effective means that fall outside direct legal regulation, in particular, the technological and Community forms of protection against spam and other issues relating to this phenomenon. The author thoroughly deals not only with the terminological problems but also, for example, with the issue of identification and proving of related legal facts, including the issue of governing law.
Associative memory (AM) is a very important part of the theory of neural networks. Although the Hebbian learning rule is always used to model the associative memory, it easily leads to spurious state because of the linear outer product method. In this work, nonlinear function constitution and dynamic synapses, against a spurious state for associative memory neural network are proposed. The model of the dynamic connection weight and the updating scheme of the states of neurons are presented. Nonlinear function constitution improves the conventional Hebbian learning rule to be a nonlinear outer product method. The simulation results show that both nonlinear function constitution and dynamic synapses can effectively enlarge the attractive basin. Comparing to the existing memory models, associative memory of neural network with nonlinear function constitution can both enlarge the attractive basin and increase the storage capacity. Owing to dynamic synapses, the attractive basin of the stored patterns is further enlarged, at the same time the attractive basin of the spurious state is diminished. But the storage capacity is decreased by using the dynamic synapses.
Anti-suit injunctions are rather unknown in the civil law legal system of the Czech Repbulic. The policy reasons for the rejection of anti-suit injunctions in the Czech Republic are rooted in the constitutional right of every person to assert, through the legally prescribed procedure, their rights before an independent and impartial court or, in specified cases, before another body. In other words, every person may commence proceedings before a competent court, or respectively before any court or another body (e.g. like an arbitral tribunal, etc.), which is then exclusively empowered to rule on its jurisdiction. Therefore, there is also no distinction between anti-suit injunctions in domestic and international litigation. Czech law does not have any alternative procedural or substantive devices that may have similar functions as anti-suit injunctions related to arbitration. It means that it is not possible to obtain a court order against a respondent prohibiting the respondent from commencing or continuing court proceedings in another forum in violation of an arbitration agreement., Alexander J. Bělohlávek., and Obsahuje bibliografické odkazy
Tumour necrosis factor (TNF) plays a central role in the inflammatory process. In the skin, it contributes to immune containment of tick-transmitted pathogens like Borrelia burgdorferi. In the saliva of some tick species, active compounds are present that inhibit detection of TNF in specific ELISA. We compared the presence of anti-TNF activity in saliva or salivary gland extract from 11 tick species from the family Ixodidae and demonstrated it in genera Ixodes Latreille, 1795 and Haemaphysalis Koch, 1844. Analysis of anti-TNF activity in Ixodes ricinus (Linnaeus, 1758) saliva during the feeding period showed that it is present in the late, rapid phase of engorgement. Significance of anti-TNF activity for tick feeding and transmission of tick-borne pathogens is discussed., Markéta Rezková, Jan Kopecký., and Obsahuje bibliografii
Skutečný stupeň reálného individuálního zestárnutí organizmu je charakterizován biologickým věkem (BV). Pomocí měření funkceschopnosti fyziologických systémů lze BV určit a hodnotu pak použít jako indikátor předčasného stárnutí. Článek přináší přehled markerů pro měření BV a definuje rozdíly mezi věkem kalendářním, biologickým a sociálním. Zahrnutí měření BV do screeningu základní prevence péče o zdraví by mělo přinést další perspektivu, jak objektivně měřit změny organizmu korespondující se stářím., Romana Mrázová, and Lit.: 15
V súčasnosti jednu z nových vzrušujúcich perspektív v onkológii predstavuje antiangiogénna liečba. Ide o liečbu zameranú na potlačenie uvoľňovania proangiogénnych faktorov, ktoré sa produkujú v bunke alebo voči receptorom pre angiogénne faktory na bunkách endotelu. Tento článok vysvetľuje princípy a aktuálne otázky antiangiogénnej terapie., Antiangiogenic therapy currently represents one of the new exciting prospects in oncology. It is a treatment that is focused on suppression of the release of proangiogenic factors produced in the cell or directed against the receptors for angiogenic factors on endothelial cells. This paper explains the principles and current issues of antiangiogenic therapy., Peter Kružliak, Jana Benkovičová, Ján Šlapák, and Lit.: 9
Východisko: Cílem retrospektivní studie bylo zhodnocení přežití bez progrese onemocnění (PFS), dále celkového přežití (OS) a odpovědi (RR) v souboru pacientů s metastatickým kolorektálním karcinomem (mCRC) léčených první linií paliativní chemoterapie v kombinaci s bevacizumabem. Sekundárním cílem byla analýza toxicity terapie a vyhodnocení vybraných prognostických a prediktivních faktorů. Pacienti a metody: V analýze byly využity některé údaje z registru AVASTIN doplněné o další klinické a laboratorní parametry. Ve vztahu k výsledku terapie jsme analyzovali i následující proměnné: věk, počet metastatických lokalizací, přítomnost mutace KRAS, přítomnost hypertenze jako komorbidity při zahájení léčby a hypertenzní reakci na léčbu bevacizumabem. Výsledky: 202 pacientů s mediánem sledování 9,7M bylo léčeno bevacizumabem (152 pacientů MOÚ a 50 pacientů FTN). Medián přežití bez známek progrese (PFS) byl 11,3 měsíců, medián celkového přežití (OS) 30,6 měsíců. Hypertenze nebyla shledána klinickým prediktivním faktorem účinku bevacizumabu. Negativní dopad na celkové přežití měla přítomnost mutace onkogenu KRAS, která neumožňuje sekvenční terapii cetuximabem. Hlavními nežádoucími účinky byly hypertenze a tromboembolické příhody. Závěr: V současnosti je terapie bevacizumabem teoreticky indikovaná téměř u všech pacientů s kolorektálním karcinomem léčených v první linii. I když jednoznačné prediktivní faktory pro odpověď na léčbu bevacizumabem dosud nebyly nalezeny, jejich hledání je výzkumnou prioritou vzhledem k vysoké finanční náročnosti antiangiogenní terapie., Background: The primary endpoint of this retrospective analysis was PFS, OS and RR in the group of the patients treated with the first line chemotherapy and bevacizumab. As secondary endopoint we also analysed a treatment toxicity and selected prognostic a and predictive factors. Patients and methods: We analysed data from AVASTIN register completed with a clinical and laboratory informations. In relation with results we analysed: age,, number of metastatic sites, KRAS status and hypertension. Results: Two hundert two pts were treated with chemotherapy and bevacizumab. The median follow up was 9,7months. The median progression-free was 11,3 months, median overall survival 30,6 months. Arterial hypertension didn´t correlate with the clinical outcome… The main adverse events were hypertension and thromboembolic events. Conclusions: Bevacizumab is a common part of the first line treatment of patients with mCRC in the Czech Republic. It should be the main point of interest to find the predictive factors of efficasy because of the high treatment expenses., Radka Obermannová, Tomáš Büchler, Michal Štícha, Jiří Navrátil, Lenka Slamová, Jana Kaňáková, Jitka Abrahámová, Rostislav Vyzula, and Lit.: 8
Na sklonku loňského roku se možnosti léčby ovariálního karcinomu rozrostly o antiangiogenní léčbu. Evropská komise schválila rozšíření indikace bevacizumabu (Avastin®): „Avastin v kombinaci s karboplatinou a paklitaxelem je indikován k úvodní léčbě pokročilého (stadia III B, III C a IV dle FIGO) epitelového nádoru vaječníků, vejcovodů nebo primárního nádoru pobřišnice“. Bevacizumab je od roku 2005 indikován k léčbě metastatického kolorektálního karcinomu a od roku 2007 k léčbě metastatického karcinomu prsu a ledviny a rekurentního či metastatického nemalobuněčného plicního karcinomu., At the end of last year, the options of treatment for ovarian cancer expanded to include antiangiogenic therapy. The European Commission approved the use of bevacizumab (Avastin®) for a new indication: “Avastin in combination with carboplatin and paclitaxel is indicated for the front-line treatment of advanced (FIGO stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.” Since 2005, bevacizumab has been indicated for the treatment of metastatic colorectal cancer and, since 2007, for the treatment of metastatic breast and kidney cancers and recurrent or metastatic non-small-cell lung cancer., František Nový, and Literatura 9